Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its second
quarter 2014 financial results and ongoing progress with IPI-145 ,
an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and
Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTCQB:SNTI)
provided an overview of the company’s current research and development
status at the 2014 BIO International Convention in San Diego.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.